» Articles » PMID: 31340181

Nanotherapeutic Silibinin: An Insight of Phytomedicine in Healthcare Reformation

Overview
Journal Nanomedicine
Publisher Elsevier
Date 2019 Jul 25
PMID 31340181
Citations 18
Authors
Affiliations
Soon will be listed here.
Abstract

Most of the herbal origin drugs possess water insoluble active constituents which lower the bioavailability and increase systemic clearance after administration of repeated or higher dose of drug. Silymarin is extracted from the seeds and fruits of milk thistle plant Silybum marianum which consists of main biologically active component as silibinin. However, the clinical applications of silibinin show some limitations due to low aqueous solubility, poor penetration into the epithelial cells of intestine, high metabolism and rapid systemic elimination. But nanotechnology-based drug delivery system explores great potential for phytochemicals to enhance the aqueous solubility and bioavailability of BCS class II and IV drugs, improve stability and modify the pharmacological activity. This review focuses on the therapeutic properties of silibinin and discusses the benefits, challenges and applications of silibinin nanoformulations. Such nanotherapeutic system as a regular medicine will be an attractive approach to reduce the adverse events and toxicities of current therapies.

Citing Articles

Development and Characterization of Silibinin-Loaded Nanoemulsions: A Promising Mucoadhesive Platform for Enhanced Mucosal Drug Delivery.

Tartari A, Jacumazo J, Lorenzett A, Freitas R, Mainardes R Pharmaceutics. 2025; 17(2).

PMID: 40006559 PMC: 11859180. DOI: 10.3390/pharmaceutics17020192.


Cardiovascular protective effects of natural flavonoids on intestinal barrier injury.

Zhou P, Xu H, Wang L Mol Cell Biochem. 2025; .

PMID: 39820766 DOI: 10.1007/s11010-025-05213-2.


Silibinin-Loaded Amphiphilic PLGA-Poloxamer Nanoparticles: Physicochemical Characterization, Release Kinetics, and Bioactivity Evaluation in Lung Cancer Cells.

Villapiano F, Piccioni M, DAria F, Crispi S, Rassu G, Giunchedi P Materials (Basel). 2024; 17(22).

PMID: 39597304 PMC: 11595691. DOI: 10.3390/ma17225480.


Silibinin inhibits PM2.5-induced liver triglyceride accumulation through enhancing the function of mitochondrial Complexes I and II.

Li D, Zhang J, Jin Y, Zhu Y, Lu X, Huo X Front Pharmacol. 2024; 15:1435230.

PMID: 39351086 PMC: 11440093. DOI: 10.3389/fphar.2024.1435230.


Synthesis, characterization, and in vitro-in ovo toxicological screening of silibinin fatty acids conjugates as prodrugs with potential biomedical applications.

Dehelean C, Alexa E, Marcovici I, Iftode A, Lazar G, Simion A Biomol Biomed. 2024; 24(6):1735-1750.

PMID: 38907734 PMC: 11496873. DOI: 10.17305/bb.2024.10600.